Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Guggenheim

Stock analysts at Guggenheim began coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report released on Monday, MarketBeat.com reports. The brokerage set a “buy” rating and a $50.00 price target on the stock. Guggenheim’s price objective would suggest a potential upside of 213.28% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Avalo Therapeutics in a research note on Thursday, January 15th. Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Avalo Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $34.88.

Avalo Therapeutics Trading Up 2.0%

NASDAQ:AVTX opened at $15.96 on Monday. The company has a market cap of $295.42 million, a price-to-earnings ratio of -2.98 and a beta of 0.88. Avalo Therapeutics has a twelve month low of $3.39 and a twelve month high of $20.72. The stock has a fifty day simple moving average of $17.30 and a 200-day simple moving average of $14.06.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($2.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.52). As a group, equities research analysts predict that Avalo Therapeutics will post -19.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in AVTX. Jennison Associates LLC bought a new position in shares of Avalo Therapeutics in the 4th quarter worth $8,637,000. Moody Aldrich Partners LLC bought a new stake in Avalo Therapeutics during the fourth quarter valued at about $2,419,000. UBS Group AG grew its stake in Avalo Therapeutics by 956.9% in the fourth quarter. UBS Group AG now owns 477,816 shares of the company’s stock valued at $8,677,000 after purchasing an additional 432,608 shares during the last quarter. Aberdeen Group plc raised its holdings in Avalo Therapeutics by 31.1% in the fourth quarter. Aberdeen Group plc now owns 95,426 shares of the company’s stock worth $1,733,000 after purchasing an additional 22,626 shares in the last quarter. Finally, PFS Partners LLC lifted its position in shares of Avalo Therapeutics by 100.0% during the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after buying an additional 1,000 shares during the last quarter. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.